Abstract

GLIMPSE ON SPLENDID AROMATASE INHIBITOR – LETROZOLE - A PRAGMATIC REVIEW

Akash Gajjar, Narendra Gajjar, Neerjesh*, Dhvani Gajjar, Shrish Raut5 and Bhavna B.

Abstract

Letrozole is the third-generation aromatase inhibitor (AI) most commonly used in assisted reproduction. It brings ovulation by inhibiting estrogen production; the consequent hypoestrogenic state enhances GnRH release and pituitary follicle-stimulating hormone (FSH) synthesis. Letrozole has fewer side effects, and a shorter halflife than clomiphene citrate, and no demonstrable effect upon the receptivity of the endometrium. It is effective in treating women with chronic anovulation, unexplained infertility and diminished ovarian reserve. Its safety is superior to clomiphene citrate. Utilizing bioequivalent doses, letrozole pregnancy rates are equal or superior to clomiphene citrate. Several studies reveal situations where it is more efficacious than gonadotropin treatment. A conclusion established was letrozole is as effective as other methods of ovulation induction. Further randomizedcontrolled studies are warranted to define more clearly the efficacy and safety of letrozole in human reproduction.

Keywords: Letrozole, unexplained infertility, diminished ovarian reserve.